GSK’s Mepolizumab: Benefit Of Going For Small Win
This article was originally published in The Pink Sheet Daily
Company almost walked away from interleukin-5 monoclonal antibody before targeting severe asthma; one mistake of big pharma has been trying “to go for a big win,” CMO Stewart says.
You may also be interested in...
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.